Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Drug Safety Announcement Blitz Highlights Gottlieb's PR Savvy As Shutdown Drags On

Jan 10 2019

• By Michael Cipriano

FDA entrance sign 2016

Related Content

Shutdown Week Three: Sponsors With Upcoming User Fee Dates Should Start Sweating

Jan 08 2019

Opioid REMS Increases Nearly Six-Fold As US FDA Adds Immediate-Release Products

Sep 19 2018

FDA examines cause of valsartan impurity

Sep 07 2018

Outpatient Rx Safety Meeting To Spotlight Health Literacy, Provider Communication

May 17 2017

Gottlieb Issues Statement On Adverse Event Limitations – An Attempt To Quell Fears?

Oct 03 2017

Dsuvia Approval May Be Followed By New Opioid Review Paradigm At FDA

Nov 02 2018

FDA Warning On Ocaliva Puts Intercept's NASH Opportunity In Jeopardy

Sep 22 2017

Gottlieb Renews Call For New Opioid Review Paradigm As Democrats Prepare For House Control

Nov 09 2018

Additional Topics

United States Drug Safety Post Market Regulation & Studies Regulation BioPharmaceutical

More from Drug Safety

More from Pink Sheet

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.